Discover why Japan is in focus
FIRM initiatives to promote Regenerative Medicine
Venue: Park Hyatt Tokyo
Opportunity: Japan currently holds 11-13% of global pharma sales making it the second largest pharma market in the world
A supportive regulatory environment: with the introduction of conditional approval, companies are able to bypass costly phase 3 trials and get their product to market quicker
Reimbursement: It is predicted that 70% of the clinical trials that follow an expedited-approval pathway will be reimbursed.